Leuthold Group LLC Has $7.01 Million Stock Position in Amgen Inc. $AMGN

Leuthold Group LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 25.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,402 shares of the medical research company’s stock after purchasing an additional 4,396 shares during the period. Leuthold Group LLC’s holdings in Amgen were worth $7,005,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Dogwood Wealth Management LLC grew its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter valued at approximately $26,000. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Morgan Stanley set a $332.00 target price on Amgen in a report on Friday, May 1st. Canaccord Genuity Group assumed coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price on the stock. Daiwa Securities Group dropped their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday. Wells Fargo & Company raised their target price on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Finally, Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $356.15.

Amgen Stock Performance

Shares of Amgen stock opened at $326.31 on Friday. The business’s fifty day simple moving average is $349.17 and its 200 day simple moving average is $342.99. The firm has a market capitalization of $176.10 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44. Amgen Inc. has a 12 month low of $267.73 and a 12 month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.15%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.